WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 for Alpha-1 Antitrypsin Deficiency
80%68%57%May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 20 • YES 60.4%May 21 • YES 65.6%May 22 • YES 66.0%May 24 • YES 76.1%
Wave Life Sciences Ltd. ($WVE)
No stock closeNo stock closeNo stock close$7.30$6.79$6.28May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 8 • WVE $7.18May 11 • WVE $7.07May 12 • WVE $6.79May 13 • WVE $6.99May 14 • WVE $6.90May 15 • WVE $6.77May 18 • WVE $6.40
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
5/18/26
Study Completion
9/1/26
Sponsor
Wave Life Sciences Ltd.
Ticker
$WVE
Type
Phase 1/Phase 2
Trial Status
Active, not recruiting
Trial Size
24
NCT
NCT06405633
Trial Description
This study tests WVE-006 in adults with Pi*ZZ alpha-1 antitrypsin deficiency, mainly tracking side effects and other medical problems through 36 weeks.